Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|January 28, 2022

Next-level Diagnosis and Compliance

Panelists provide pearls on how to make a smarter diagnosis, tailor treatment plans to patients’ lifestyles and preferences, and motivate pediatric patients to adhere to their treatment plan.

Episodes in this series

EP. 1 Meet the Experts

EP. 1 Meet the Experts

EP. 2 Patient Assessment: Get the Patient’s History, Then Get Their Story

EP. 2 Patient Assessment: Get the Patient’s History, Then Get Their Story

EP. 3 Tackling Tough Issues: How to Talk to Patients and Their Families

EP. 3 Tackling Tough Issues: How to Talk to Patients and Their Families

EP. 4 Next-level Diagnosis and Compliance

EP. 4 Next-level Diagnosis and Compliance

EP. 5 Acne’s Unseen Pain

EP. 5 Acne’s Unseen Pain

EP. 6 What’s New?

EP. 6 What’s New?

EP. 7 Q&A

EP. 7 Q&A

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction

The Year So Far in GLP-1s: What Psychiatric Clinicians Need to Know

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness